Psychedelic Science Newsletter
Issue #64November 16, 20267 studies

A single psilocybin dose shifted self-perception and cut depression scores in 37 patients

Psychedelic research had a busy week — new trial data, a neuroscience deep-dive, and one very alarming mushroom.

Here's what the evidence actually showed.

🍄 One Dose, Two Weeks, a Different Sense of Self

  • In a randomized, double-blind trial of 37 people with major depressive disorder, a single moderate psilocybin dose produced significant reductions in depressive symptoms and a measurable increase in positive self-concept within two weeks — compared to placebo.
  • The self-concept shift wasn't decorative: it correlated directly with how much depression scores dropped, suggesting the two are meaningfully linked rather than coincidental.
  • Brain imaging added a specific wrinkle: psilocybin changed how the caudate — a region tied to attention and reward — activated during self-referential thinking, while placebo produced the opposite pattern.

Why it matters: This is one of the cleaner controlled datasets connecting psilocybin's psychological effects (how you think about yourself) to its clinical effects (how depressed you feel), with a neural mechanism to interrogate further.

🎖️ Top 10% journal 🔗 Philos Trans R Soc Lond B Biol Sci Randomized Controlled Trial 🗓️ Nov 10

Key Findings

🍄☠️ The Mushroom That's Both Magic and Deadly

  • Researchers identified Galerina indica — dubbed the "dark magic mushroom" — as the first known fungal species to produce both psilocybin and amatoxins, the compounds responsible for deadly poisonings.
  • Genomic analysis suggests psilocybin biosynthesis arrived via horizontal gene transfer, essentially bolted onto a species that already made lethal toxins. The ecological implications of that combination are unresolved.
💡 Nature built a mushroom that is simultaneously psychedelic and potentially fatal.
🔗 Current biology : CB Journal Article 🗓️ Nov 11

🧠 LSD Pushes Gene Expression Away from Brain Aging Patterns

  • Transcriptomic analyses across rats and mice showed that LSD treatment produced gene expression profiles strongly anti-correlated with aging-associated changes in the human prefrontal cortex — and the pattern held across multiple doses and datasets.
  • In lab-grown cortical cells, short-term LSD treatment also reduced structural and molecular changes triggered by amyloid-beta, the protein fragment implicated in Alzheimer's disease.
💡 LSD's gene-expression fingerprint runs counter to brain-aging signatures, at least in animals.
🥉 Top 5% journal 🔗 Aging cell Journal Article 🗓️ Nov 10

💊 Ibogaine's Benefits in Veterans Held at 12 Months

  • In 25 male Special Operations veterans with traumatic brain injury histories, improvements in disability, PTSD, depression, and anxiety observed after a single magnesium-ibogaine treatment remained large and statistically robust through 12 months.
  • Caveat worth noting: most participants used other psychedelic substances or pursued additional interventions during follow-up, making ibogaine's standalone contribution difficult to isolate.
💡 Ibogaine's effects in TBI veterans persisted a year out, but the follow-up period wasn't clean.
🥉 Top 5% journal 🔗 Translational psychiatry Journal Article 🗓️ Nov 9

🔗 Feeling Connected May Explain Psilocybin Retreat Benefits

  • A prospective naturalistic study found that increased sense of connectedness — to others, nature, or something larger — emerged as a candidate pathway linking psilocybin retreat experiences to sustained improvements in wellbeing outside clinical settings.
  • The finding matters for public mental health framing: it suggests retreats may work partly through social and relational mechanisms, not just pharmacology.
💡 Connectedness, not just the drug, may be doing meaningful work at psilocybin retreats.
Top 20% journal 🔗 Frontiers in psychiatry Journal Article 🗓️ Nov 12

💉 Ketamine Rewires Serotonin Circuits in Circuit-Specific Ways

  • Animal research showed ketamine increased the firing of serotonin-producing neurons in the dorsal raphe while simultaneously strengthening some glutamate inputs and weakening others — depending on where those neurons projected in the brain.
  • The synaptic strengthening toward the prefrontal cortex required a growth-factor receptor signal; the firing-rate increase did not. Two parallel pathways, not one.
💡 Ketamine's serotonin effects are more wiring-specific than a simple "more serotonin" story.
🎖️ Top 10% journal 🔗 iScience Journal Article 🗓️ Nov 12

💻 Ketamine Clinic Websites in South Florida Raised Safety Transparency Concerns

  • A cross-sectional audit of ketamine clinic websites in South Florida found that direct-to-consumer information was subject to limited oversight, with incomplete or potentially misleading disclosures about safety risks and regulatory status.
  • As clinics expand rapidly across the U.S., the gap between what patients read online and what they need to make informed decisions represents a concrete, underaddressed problem.
💡 Ketamine clinic websites are outpacing the oversight meant to keep patients informed.
🔗 Journal of psychiatric practice Journal Article 🗓️ Nov 11

Implications

Psilocybin, ketamine, ibogaine, and LSD each showed distinct but converging signals this week — from self-concept shifts to gene expression patterns to year-long symptom relief. The unresolved tension: most of these findings are small, unblinded, or animal-based, and the field still lacks consensus on which mechanisms actually drive durable human outcomes.

Studies in this issue

Primary sources used for this newsletter.

  1. Changes in self-thinking and depression severity after one moderate dose of psilocybin in depressed patients
    main storyPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2026-11-10PMID 43007824
  2. Feeling connected may link experiences at psilocybin retreats to lasting wellbeing
    key findingFrontiers in psychiatry2026-11-12PMID 43016926
  3. Patient Safety and Regulation Information on Ketamine Clinic Websites in South Florida
    key findingJournal of psychiatric practice2026-11-11PMID 43013865